NCT06325826

The Study of the Validation of General Evaluation Score (GES) in the Prediction of Hepatocellular Carcinoma Risk Among Patients With Advanced Fibrosis and Cirrhosis Who Achieved Sustained Virological Response for Hepatitis C Virus After Direct Acting Antiviral Drugs

Name: Clinical Trial NCT06325826
Creator: Egyptian Liver Hospital
Keywords: Hepatocellular Carcinoma, General Evaluation Score (GES), diagnostic test, clinical trial, Egypt

Egyptian Liver Hospital·ClinicalTrials.gov·diagnostic testRecruitment Completed

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Hepatocellular Carcinoma
Drug/Device/Intervention: General Evaluation Score (GES)
Study type: Observational
Intervention type: diagnostic test

Sponsor & location

Primary sponsor: Egyptian Liver Hospital
Location: Talkha, Egypt

Timeline & enrollment

Phase: N/A
Start date: Feb 01, 2022
End date: Jun 30, 2025
Enrollment: 500 participants

Primary outcome

Hepatocellular Carcinoma

Summary

This cohort study aims to evaluate the validation of general evaluation score in the prediction of hepatocellular carcinoma risk among patients with advanced fibrosis (F3) and cirrhosis (F4) who achieved sustained virological response for hepatitis c virus after direct acting antiviral drugs and determine the group of these patients who require intensified surveillance.

ICD-10 classifications

Malignant neoplasm: HepatoblastomaMalignant neoplasm: Liver cell carcinomaMalignant neoplasm: Other specified carcinomas of liverMalignant neoplasm: Liver, unspecifiedMalignant neoplasm: Hepatic flexure

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06325826
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06325826 through Pure Global AI's free database. This phase not specified trial is sponsored by Egyptian Liver Hospital and is currently Recruitment Completed. The study focuses on Hepatocellular Carcinoma. Target enrollment is 500 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.